financetom
Business
financetom
/
Business
/
What's Going On With Lululemon Athletica Stock Tuesday?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
What's Going On With Lululemon Athletica Stock Tuesday?
Mar 17, 2026 12:01 PM

Lululemon Athletica Inc. ( LULU ) shares are up on Tuesday as the company is facing scrutiny from shareholders regarding its leadership and strategic direction.

The firm will release its financial results for the fourth quarter and full year fiscal 2025 today (Tuesday, March 17, 2026). The company will host a conference call at 4:30 p.m. Eastern time to discuss the results.

Chip Wilson, the founder and a significant shareholder of Lululemon, has publicly called for the company’s leadership to address critical questions about its future direction.

“As Lululemon reports its fourth quarter and full year 2025 results, shareholders will be critically evaluating the company’s claims of success or improvement,” per Wilson’s statement in a release. “The core issue at Lululemon is one the company has struggled with for years: there is a disconnect between the company’s creative engine and the Board’s understanding for how brand power and product excellence fuel cultural strength, margin durability and long-term shareholder value.”

Wilson emphasized the need for accountability and oversight, particularly regarding the disconnect between the company’s creative vision and the board’s understanding of brand power, which he believes is essential for long-term shareholder value.

Founder’s Board Proxy Battle

On March 5, Wilson launched CreativityFirstlulu.com to campaign for a leadership overhaul and strategic shift at the company. Wilson has nominated three independent director candidates—Marc Maurer, Laura Gentile, and Eric Hirshberg—to infuse the board with creative and brand-first expertise.

The campaign focuses on renewing product excellence and recommitting to the brand’s original identity ahead of the appointment of a new CEO.

Technical Analysis

Currently, Lululemon is trading 7.1% below its 20-day simple moving average (SMA) and 12.1% below its 50-day SMA, indicating a bearish trend in the short to medium term. Over the past 12 months, shares have decreased by 50.55%, and the stock is positioned closer to its 52-week lows than its highs, reflecting significant downward pressure.

The RSI is at 33.20, which is considered neutral territory, suggesting that the stock is neither overbought nor oversold at this time. Meanwhile, the MACD is at -6.2892, below its signal line at -4.7313, indicating bearish momentum in the stock’s price action.

The combination of neutral RSI and bearish MACD suggests mixed momentum, indicating that while the stock is not in an oversold condition, the bearish MACD signals caution for potential buyers.

Key Resistance: $184.50

Key Support: $161.00

Analyst Consensus & Recent Actions: The stock carries a Hold Rating with an average price target of $199.89. Recent analyst moves include:

Evercore ISI Group: In-Line (Lowers Target to $175.00) (Mar. 16)

BTIG: Buy (Lowers Target to $250.00) (Mar. 12)

Goldman Sachs: Neutral (Lowers Target to $184.00) (Mar. 11)

Top ETF Exposure

Invesco ESG NASDAQ Next Gen 100 ETF : 1.91% Weight

Significance: Because LULU carries meaningful weight in these funds, any significant inflows or outflows for these ETFs will likely force automatic buying or selling of the stock.

LULU Price Action: Lululemon Athletica ( LULU ) shares were up 1.08% at $161.63 at the time of publication on Tuesday. The stock is trading near its 52-week low of $156.63, according to Benzinga Pro data.

Image via Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's lung'
US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's lung'
Sep 29, 2024
Sept 27 (Reuters) - The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease commonly known as smoker's lung, the companies said on Friday. (Reporting by Sriparna Roy in Bengaluru; Editing by Sriraj Kalluvila) ...
WeightWatchers CEO Sima Sistani steps down after over 2-year stint
WeightWatchers CEO Sima Sistani steps down after over 2-year stint
Sep 29, 2024
Sept 27 (Reuters) - WW International ( WW ), also known as WeightWatchers, said on Friday CEO Sima Sistani was stepping down and that insider Tara Comonte would succeed her on an interim basis. During Sistani's two-and-a-half-year tenure, WeightWatchers in 2023 acquired the telehealth platform Sequence, now known as WeightWatchers Clinic, expanding into obesity drug prescriptions. Despite this, the company's...
Foresight, BuilderX Partner to Develop, Commercialize 3D Offering for Construction Machinery, Equipment
Foresight, BuilderX Partner to Develop, Commercialize 3D Offering for Construction Machinery, Equipment
Sep 29, 2024
09:31 AM EDT, 09/27/2024 (MT Newswires) -- Foresight Autonomous Holdings ( FRSX ) said Friday that it has collaborated with Chinese construction equipment firm BuilderX to develop and commercialize 3D perception offering for construction machinery and equipment. Financial terms of the collaboration were not disclosed. Foresight said it will integrate its stereoscopic technology with BuilderX's remote-controlled consoles. In the long...
Blink Charging Surpasses 100,000 Charger Milestone
Blink Charging Surpasses 100,000 Charger Milestone
Sep 29, 2024
09:38 AM EDT, 09/27/2024 (MT Newswires) -- Blink Charging ( BLNK ) said Friday it has sold, deployed or contracted over 100,000 chargers worldwide. The chief executive of the electric vehicle charging company, Brendan Jones, said the milestone was mainly due to various factors, including its turnkey model that allows streamlined project management from start to installation. Shares of Blink...
Copyright 2023-2026 - www.financetom.com All Rights Reserved